Clinical Trial Update: A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas [Phase 2]

View source ↗

Summary

A Phase II study of PXD101 (belinostat) in recurrent or refractory cutaneous T-cell lymphoma and peripheral T-cell lymphoma was terminated; results have been po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous T-cell Lymphoma
• Non-hodgkin Lymphoma
• Peripheral T-cell Lymphoma

Drugs mentioned

• PXD101

Snippet

Sponsor: Valerio Therapeutics | Conditions: Cutaneous T-Cell Lymphoma, Peripheral T-Cell Lymphoma | Phase 2 | Status: TERMINATED | Results posted: 2014-10-27